Background: The indication of living donor liver retransplantation (re-LDLT) for retransplant candidates with chronic allograft failure (CAF) is increasing because of the high mortality rate of patients on the waiting list. However, evidence supporting re-LDLT for CAF remains scarce because of technical difficulties. We aimed to examine the feasibility based on our significant case experience.
Methods: A total of 95 retransplant cases (adult: 53, pediatric: 42) between 2000 and 2020 were retrospectively reviewed. Graft survival after re-LDLT and deceased donor liver retransplantation (re-DDLT) was compared among recipients with CAF and acute allograft failure (AAF).
Results: Re-LDLTs for CAF were performed in 58 (61.1%) cases, re-DDLTs for CAF in 16 (16.8%) cases, re-LDLTs for AAF in 13 (13.7%) cases, and re-DDLTs for AAF in 8 (8.4%) cases. Re-DDLTs have become increasingly prevalent over time. Retransplantation for AAF results in lower graft survival than that for CAF in both adult and pediatric cases. All adult recipients who underwent re-LDLT for AAF died within 1 y after retransplantation. The 5-y graft survival between re-LDLT and re-DDLT for CAF was not significantly different (73.8% versus 75.0%, P = 0.84). Operation time and blood loss were not significantly different.
Conclusions: The survival rate of re-LDLT for recipients with CAF is permissible. Re-LDLT may be another treatment option for recipients with CAF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/TP.0000000000005164 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of pediatric liver retransplantation candidates in the modern era: Strategies are needed to avoid waitlist mortality in the United States.
Liver Transpl
January 2025
Division of Transplantation, Department of Surgery, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA.
Pediatric liver retransplantation (rLT) has historically shown poorer outcomes compared to primary liver transplantation (pLT). Comprehensive studies assessing outcomes for pediatric rLT candidates under the modern allocation policy are lacking. OPTN data from January 1, 2010, to December 31, 2022 were obtained; exclusion criteria included candidates ≥18years of age and those listed or transplanted for multiple organs.
View Article and Find Full Text PDFHeart Transplantation Outcomes for Fontan Patients When Using Contemporary Strategies: Heart-Liver Transplantation and Ventricular Assist Device Therapy.
World J Pediatr Congenit Heart Surg
January 2025
The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Background: With an increasing number of Fontan patients surviving into adulthood, the burden of end-stage heart failure is increasing. Prior studies have reported suboptimal heart transplantation (HTx) outcomes. Therefore, the authors describe their institutional experience of HTx in patients with Fontan circulation failure, including heart-liver transplantation (HLTx) and pretransplant systemic ventricular assist device (SVAD) therapies.
View Article and Find Full Text PDFLiver stiffness: a novel imaging biomarker by ultrasound elastography for prediction of early allograft failure following liver transplantation.
Abdom Radiol (NY)
January 2025
Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
Objectives: The objective of this study was to evaluate the role of Liver Stiffness Measurement (LSM) and serum transaminase levels for predicting early allograft failure (EAF) after liver transplantation (LT).
Methods: A total of 189 patients who underwent LT were prospectively recruited in the study. Of these patients, 13 cases died or received re-transplantation within 90 days after surgery were classified as EAF group, while rest 176 patients were included in the non-EAF group.
Liver Transplantation for Polycystic Disease: Experience and Results of a Single-Center Series.
Transplant Proc
January 2025
Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, Bilbao, Spain; BioBizkaia Research Health Institute, Barakaldo, Bizkaia, Spain. Electronic address:
Polycystic liver disease (PLD) is a hereditary condition, and its symptoms are due to the growth of cysts. Liver transplantation (LT) is the only curative treatment. A retrospective single-center analysis was conducted on the 10 LTs performed for PLD between 2004 and 2023.
View Article and Find Full Text PDFValidation of mitochondrial FMN as a predictor for early allograft dysfunction and patient survival measured during hypothermic oxygenated perfusion.
Liver Transpl
October 2024
Department of General Surgery, Division of Transplantation, Medical University of Vienna, Vienna, Austria.
Hypothermic oxygenated machine perfusion (HOPE) preconditions liver grafts before transplantation. While beneficial effects on patient outcomes were demonstrated, biomarkers for viability assessment during HOPE are scarce and lack validation. This study aims to validate the predictive potential of perfusate flavin mononucleotide (FMN) during HOPE to enable the implementation of FMN-based assessment into clinical routine and to identify safe organ acceptance thresholds.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!